Molecular insights into fosfomycin resistance in Escherichia coli. 2017

M Ballestero-Téllez, and F Docobo-Pérez, and I Portillo-Calderón, and J M Rodríguez-Martínez, and L Racero, and M S Ramos-Guelfo, and J Blázquez, and J Rodríguez-Baño, and A Pascual

Fosfomycin activity in Escherichia coli depends on several genes of unknown importance for fosfomycin resistance. The objective was to characterize the role of uhpT , glpT , cyaA and ptsI genes in fosfomycin resistance in E. coli. WT E. coli BW25113 and null mutants, Δ uhpT , Δ glpT , Δ cyaA , Δ ptsI , Δ glpT-uhpT , Δ glpT-cyaA , Δ glpT-ptsI , Δ uhpT-cyaA , Δ uhpT-ptsI and Δ ptsI-cyaA , were studied. Susceptibility to fosfomycin was tested using CLSI guidelines. Fosfomycin mutant frequencies were determined at concentrations of 64 and 256 mg/L. Fosfomycin in vitro activity was tested using time-kill assays at concentrations of 64 and 307 mg/L (human C max ). Fosfomycin MICs were: WT E. coli BW25113 (2 mg/L), Δ glpT (2 mg/L), Δ uhpT (64 mg/L), Δ cyaA (8 mg/L), Δ ptsI (2 mg/L), Δ glpT-uhpT (256 mg/L), Δ glpT-cyaA (8 mg/L), Δ glpT-ptsI (2 mg/L), Δ uhpT-cyaA (512 mg/L), Δ uhpT-ptsI (64 mg/L) and Δ ptsI-cyaA (32 mg/L). In the mutant frequency assays, no mutants were recovered from BW25113. Mutants appeared in Δ glpT , Δ uhpT , Δ cyaA and Δ ptsI at 64 mg/L and in Δ uhpT and Δ cyaA at 256 mg/L. Δ glpT-ptsI , but not Δ glpT-cyaA , Δ uhpT-cyaA or Δ uhpT-ptsI , increased the mutant frequency compared with the highest frequency found in each single mutant. In time-kill assays, all mutants regrew at 64 mg/L. Initial bacterial reductions of 2-4 log 10 cfu/mL were observed for all strains, except for Δ uhpT-ptsI , Δ glpT-uhpT and Δ uhpT-cyaA . Only Δ glpT and Δ ptsI mutants were cleared using 307 mg/L. Fosfomycin MIC may not be a good efficacy predictor, as highly resistant mutants may appear, depending on other pre-existing mutations with no impact on MIC.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004269 DNA, Bacterial Deoxyribonucleic acid that makes up the genetic material of bacteria. Bacterial DNA
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D005578 Fosfomycin An antibiotic produced by Streptomyces fradiae. Phosphonomycin,Fosfomycin Trometamol Salt,Fosfomycin Tromethamine,Monuril,Phosphomycin,Tromethamine, Fosfomycin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D019450 Genes, MDR Genes for MEMBRANE TRANSPORT PROTEINS that confer resistance to toxic compounds. Several superfamilies of these multidrug export proteins are known and found in both prokaryotes and eukaryotes. MDR Genes,Multidrug Resistance Gene,Multidrug Efflux Pump Genes,Gene, MDR,Gene, Multidrug Resistance,Genes, Multidrug Resistance,MDR Gene,Multidrug Resistance Genes,Resistance Gene, Multidrug,Resistance Genes, Multidrug
D024881 Drug Resistance, Bacterial The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance, Bacterial,Antibacterial Drug Resistance
D029968 Escherichia coli Proteins Proteins obtained from ESCHERICHIA COLI. E coli Proteins

Related Publications

M Ballestero-Téllez, and F Docobo-Pérez, and I Portillo-Calderón, and J M Rodríguez-Martínez, and L Racero, and M S Ramos-Guelfo, and J Blázquez, and J Rodríguez-Baño, and A Pascual
April 1982, Antimicrobial agents and chemotherapy,
M Ballestero-Téllez, and F Docobo-Pérez, and I Portillo-Calderón, and J M Rodríguez-Martínez, and L Racero, and M S Ramos-Guelfo, and J Blázquez, and J Rodríguez-Baño, and A Pascual
April 2010, International journal of antimicrobial agents,
M Ballestero-Téllez, and F Docobo-Pérez, and I Portillo-Calderón, and J M Rodríguez-Martínez, and L Racero, and M S Ramos-Guelfo, and J Blázquez, and J Rodríguez-Baño, and A Pascual
June 2024, Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology],
M Ballestero-Téllez, and F Docobo-Pérez, and I Portillo-Calderón, and J M Rodríguez-Martínez, and L Racero, and M S Ramos-Guelfo, and J Blázquez, and J Rodríguez-Baño, and A Pascual
September 1998, The Journal of antibiotics,
M Ballestero-Téllez, and F Docobo-Pérez, and I Portillo-Calderón, and J M Rodríguez-Martínez, and L Racero, and M S Ramos-Guelfo, and J Blázquez, and J Rodríguez-Baño, and A Pascual
November 2015, Emerging infectious diseases,
M Ballestero-Téllez, and F Docobo-Pérez, and I Portillo-Calderón, and J M Rodríguez-Martínez, and L Racero, and M S Ramos-Guelfo, and J Blázquez, and J Rodríguez-Baño, and A Pascual
September 2018, Journal of global antimicrobial resistance,
M Ballestero-Téllez, and F Docobo-Pérez, and I Portillo-Calderón, and J M Rodríguez-Martínez, and L Racero, and M S Ramos-Guelfo, and J Blázquez, and J Rodríguez-Baño, and A Pascual
December 2018, Future microbiology,
M Ballestero-Téllez, and F Docobo-Pérez, and I Portillo-Calderón, and J M Rodríguez-Martínez, and L Racero, and M S Ramos-Guelfo, and J Blázquez, and J Rodríguez-Baño, and A Pascual
January 2019, Journal of clinical microbiology,
M Ballestero-Téllez, and F Docobo-Pérez, and I Portillo-Calderón, and J M Rodríguez-Martínez, and L Racero, and M S Ramos-Guelfo, and J Blázquez, and J Rodríguez-Baño, and A Pascual
December 1985, Journal of general microbiology,
M Ballestero-Téllez, and F Docobo-Pérez, and I Portillo-Calderón, and J M Rodríguez-Martínez, and L Racero, and M S Ramos-Guelfo, and J Blázquez, and J Rodríguez-Baño, and A Pascual
August 1983, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!